Premarin discontinued in Canada: Pfizer has confirmed it will stop selling its Premarin menopause hormone therapy in Canada after an internal review, Reuters reported on 12 November 2026. The vaginal cream has been short since June and no more batches will be supplied, while remaining stocks of the 0.3 mg, 0.625 mg and 1.25 mg oral tablets are expected to last until around mid-2027. Pfizer said the move is not linked to any new safety, efficacy or quality concern.
For the many Canadian women who rely on the product, the practical question is not why Pfizer left but how quickly to plan a switch. Below is what is changing, what is not, and what the exit says about the economics of older hormone brands.
Key takeaways on Premarin discontinued in Canada
- All retail Premarin in Canada is affected: the vaginal cream (already unavailable) and three tablet strengths.
- Tablet supply should run to roughly mid-2027, but could end sooner if patients stockpile or demand jumps.
- Premarin Intravenous, a hospital product for abnormal uterine bleeding, is not affected.
- Pfizer says other treatments remain available in Canada and the decision is commercial, not safety-related.
- Pfizer already suspended Premarin vaginal cream sales in India in July 2026.
What exactly is ending, and when
| Premarin product | Canadian status | Timing |
|---|---|---|
| Vaginal cream | In shortage; no further batches | Short since June 2026 |
| Oral tablets 0.3 mg / 0.625 mg / 1.25 mg | Being discontinued | Stock expected to last to about mid-2027 |
| Premarin Intravenous (hospital) | Not affected | Continues |
The cream matters most in the near term. Premarin vaginal cream is used for local menopause symptoms such as vaginal dryness and painful intercourse, part of what clinicians call genitourinary syndrome of menopause. Patients who were waiting for it to come back now know it will not. Tablet users have more runway, roughly six to eight months by our calculation from today to mid-2027, though the company warned that a demand spike could shorten that.
Why a company would walk away from a 1940s brand
Premarin, made from conjugated estrogens, is one of the oldest branded drugs still on the market. Pfizer gave no commercial detail beyond an internal review, so the reasoning below is analysis, not company disclosure. Mature products with complex, natural-source manufacturing tend to carry high production costs relative to the prices they command in smaller markets. When a supply chain is already strained, as the months-long cream shortage suggests, keeping a low-volume market supplied can stop making sense. The pattern in India, where the cream was suspended in July, points the same way: Pfizer appears to be trimming smaller markets rather than the brand as a whole.
Pfizer declined to comment on supply in the United States, Australia, New Zealand or Singapore, where Premarin is also sold. There is no report of any US withdrawal.
A tight moment for hormone therapy supply
The timing is awkward. Demand for menopause hormone therapy has climbed, particularly in the US after the FDA removed long-standing boxed safety warnings in November 2025, and prescriptions have risen since. In Canada, Health Canada said earlier in November that certain strengths of estradiol transdermal patches from Bayer and Sandoz were in short supply, with intermittent shortages expected until early 2027. That means some patients moving off Premarin tablets may find their first alternative is also hard to fill.
Generic makers have been moving in on the category elsewhere; see our report on Zydus and its menopause patch exclusivity. For Pfizer’s wider portfolio priorities, our analysis of the Pfizer Blackstone obesity funding deal shows where the company is putting its money.
What patients in Canada can do now
Switching hormone therapy is a clinical decision, and this article does not offer dosing advice. In general terms, other estrogen products exist in Canada in several forms, including estradiol tablets, patches and gels for whole-body symptoms, and locally applied vaginal estrogen in creams, tablets or rings for local symptoms. They are not identical to conjugated estrogens, so doses are not interchangeable one-for-one. Sensible steps include booking a review with a prescriber or pharmacist well before current supply runs out, asking whether a local rather than systemic product fits the symptoms, and checking that any replacement is actually in stock locally. Women who also take a progestogen to protect the uterus should keep that part of their regimen unchanged unless their doctor advises otherwise.
Market context
The broader hormone therapy business is growing even as individual legacy brands retreat. Acumen Research and Consulting sized the global hormone replacement therapy market at US$21.6 billion in 2022 and projects US$39.8 billion by 2032, a 6.4% compound annual growth rate. North America holds the largest share, oral products led by route of administration, and Asia-Pacific is expected to grow fastest. Growth driven by generics and newer delivery forms helps explain why an originator can exit a market without patients losing access to the drug class.
Open questions
- Will Health Canada add Premarin to its discontinuation database with a firm end date?
- Will any company seek to supply a conjugated estrogen product in Canada once Pfizer leaves?
- Could other smaller markets follow Canada and India?
FAQ
Is Premarin being discontinued in Canada?
Yes. Pfizer will stop selling Premarin vaginal cream and oral tablets in Canada. Tablets should remain available until around mid-2027 while stock lasts.
Why is Premarin cream unavailable?
The cream has been in shortage in Canada since June 2026, and Pfizer says no further batches will be supplied. The company said the decision is not tied to safety, efficacy or quality problems.
Is Premarin discontinued in the US?
There is no report of a US discontinuation. Pfizer declined to comment on supply outside Canada.
What can replace Premarin?
Other estrogen therapies, such as estradiol pills, patches, gels and vaginal products, are available in Canada. The right switch depends on symptoms and health history, so speak with a prescriber.
Sources: Pfizer Canada statements via Reuters (12 Nov 2026); Health Canada shortage notices as reported by Reuters. Market data: Acumen Research and Consulting. More in our Pharmaceuticals section. This article is for information only and is not medical or investment advice. Last updated 13 November 2026.
